ViVac Pharma receives NIS 100,000 award for its work on programmable RNA immunotherapies targeting solid tumors. | Read More in JPost.com – Business & Innovation | The Jerusalem Post
Lebanon doesn’t meet minimum standard for eliminating human trafficking, US State Dept. finds
What does Tom Barrack’s warning on Saudi Arabia reveal about US Middle East policy? – analysis
Are newsrooms burying Iranian efforts to influence midterms? – opinionAre newsrooms burying Iranian efforts to influence midterms? – opinion
A generation in economic crisis: Europe’s young people take to the streets as protests spread
IDF will ‘allow democratic elections to take place without external interference,’ says IDF chief
‘Bombing will resume sooner or later’: Iran prepares for US-Israeli attacks amid Hormuz tensions
IDF gives detained Chabad students a choice: enlist or face prison
Was Israel warned before the October 7 attacks?
A little girl, a family’s world, and a fight no child should ever face
Pakistan steps in as US-Iran tensions threaten renewed conflict
Katz threatens to expand control in Lebanon if Hezbollah attacksHebrew University start-up wins Asper Prize for approach to cancer treatmentLebanon doesn’t meet minimum standard for eliminating human trafficking, US State Dept. finds